Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29921612 | 1.00 | AR (0.78) | ARPGR | |
| SCHEMBL4027208 | 0.90 | AR (0.74) | ARPGR | |
| SCHEMBL23260981 | 0.89 | AR (0.72) | AR | |
| SCHEMBL1387845 | 0.89 | AR (0.62) | ARPGR | |
| SCHEMBL1389052 | 0.89 | AR (0.72) | ARPGR | |
| SCHEMBL8174307 | 0.88 | AR (0.72) | ARPGR | |
| SCHEMBL7759712 | 0.88 | AR (0.66) | ARPGR | |
| SCHEMBL633857 | 0.88 | AR (0.71) | ARPGR | |
| SCHEMBL8704575 | 0.88 | AR (0.77) | ARPGR | |
| SCHEMBL7783753 | 0.88 | AR (0.77) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357513-B1 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-3527210-B1 | COMBINED COMPOSITION COMPRISING A BENZOHETEROCYCLIC COMPOUND AND AN ANDROGEN RECEPTOR PATHWAY MODULATOR AND USES THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-10933059-B2 | Combination, application thereof and treatment method | KANGPU BIOPHARMACEUTICALS. LTD. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-20190328722-A1 | COMBINATION, APPLICATION THEREOF AND TREATMENT METHOD | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
| EP-3527210-A1 | COMPOSITION, APPLICATION THEREOF AND TREATMENT METHOD | Kangpu Biopharmaceuticals, Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-3357513-A1 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2018-08-08 | — | — | EP | disclosed |
| US-9205102-B2 | Method for treatment of castration-resistant prostate cancer | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-12-08 | — | — | US | disclosed |
| US-9205102-B2 | Method for treatment of castration-resistant prostate cancer | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-12-08 | — | — | US | disclosed |
| US-20150157656-A1 | Method for Treatment of Castration-Resistant Prostate Cancer | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-06-11 | — | — | US | disclosed |
| US-20150157656-A1 | Method for Treatment of Castration-Resistant Prostate Cancer | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-06-11 | — | — | US | disclosed |
| EP-0671156-B1 | Process to prepare cosmetic or pharmaceutical compositions containing liposomes | AVENTIS PHARMA SA (FR) | 2001-10-24 | — | — | EP | disclosed |
| US-6162444-A | Cosmetic or pharmaceutical compositions | HOECHST MARION ROUSSEL (FR) | 2000-12-19 | — | — | US | disclosed |
| CN-1049214-C | Phenylimidazolidines, process for their preparation, their use as medicaments and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 2000-02-09 | — | — | CN | disclosed |
| US-RE35956-E | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1998-11-10 | — | — | US | disclosed |
| US-5627201-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1997-05-06 | — | — | US | disclosed |
| EP-0494819-B1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1996-07-10 | — | — | EP | disclosed |
| EP-0671156-A1 | Cosmetic or pharmaceutical compositions containing liposomes | ROUSSEL UCLAF (FR) | 1995-09-13 | — | — | EP | disclosed |
| US-5411981-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1995-05-02 | — | — | US | disclosed |
| CN-1063102-A | New phenylimidazolidines,, prepare they method, they are as the application of medicine and the pharmaceutical composition that contains them | ROUSSEL UCLAF (FR) | 1992-07-29 | — | — | CN | disclosed |
| EP-0494819-A1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328722-A1 | COMBINATION, APPLICATION THEREOF AND TREATMENT METHOD | CYP21A2, CYP17A1, NR5A1 | AR 5/4885PGR 96/4885 |
| US-10933059-B2 | Combination, application thereof and treatment method | CYP21A2, CYP17A1, NR5A1 | AR 5/4885PGR 96/4885 |
| US-20150157656-A1 | Method for Treatment of Castration-Resistant Prostate Cancer | IGFBP5, IGFBP2, IGFBP1 | AR 7/4885PGR 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.